Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is a rare, aggressive malignancy with limited effective treatment options.
• Conventional therapies offer poor outcomes for most ATC patients, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To identify and evaluate novel therapeutic compounds for anaplastic thyroid cancer.
• To investigate the efficacy of the JAK2 inhibitor Lestaurtinib as a potential targeted therapy for ATC.

Main Methods:

• Screening of 13 ATC cell lines to identify potent anti-cancer compounds.
• In vitro assays including proliferation, migration, and colony formation.
• Cell cycle analysis using flow cytometry.
• In vivo efficacy studies utilizing chick chorioallantoic membrane xenograft models with ultrasound imaging.

Main Results:

• Lestaurtinib demonstrated potent in vitro antiproliferative effects at nanomolar concentrations.
• The drug inhibited cell migration, colony formation, and induced G2/M cell cycle arrest.
• In vivo studies showed a significant reduction in tumor volume and vascularity following Lestaurtinib treatment.

Conclusions:

• Lestaurtinib exhibits significant antiproliferative and antiangiogenic activity against anaplastic thyroid cancer.
• These findings support Lestaurtinib as a promising candidate for targeted therapy development in ATC.
• Further clinical investigation of Lestaurtinib for ATC treatment is warranted.